C5839-72M
CLEC9a (C-type Lectin Domain Family 9 Member A, UNQ9341/PRO34046)
Größe
£965.00
- SKU:
- C5839-72M
- Reinheit:
- Purified by immunoaffinity chromatography. Endotoxin: ≤0.1EU/ug (LAL).
- Lagerbedingungen:
- -20°C
- Hersteller:
- United States Biological
- Host:
- Sheep
- Immunogen:
- Recombinant protein corresponding to Lys57-Val241 from human CLEC9 expressed in NS0 cell line.
- Format:
- Supplied as a lyophilized powder in PBS, 5% trehalose. Reconstitute with 500ul sterile PBS.
- Weitere Details:
- CLEC9a also known as DNGR-1, is a type II transmembrane glycoprotein member of the C-type lectin superfamily. Mature human CLEC9a consists of a 35aa cytoplasmic domain with an ITAM-like motif, a 21aa transmembrane segment, and a 185 extracellular domain (ECD) that contains a stalk region and one C-type lectin domain (CTLD). Within the ECD, human CLEC9a shares 57% aa sequence identity with mouse and rat CLEC9a. Although the CTLD of CLEC9a structurally resembles that of other C-type lectins, it lacks the conserved residues that typically mediate calcium and carbohydrate binding. CLEC9a is expressed as a disulfide-linked homodimer of ~45-50kD N-glycosylated subunits. Human CLEC9a expression is restricted to a subpopulation of BDCA-3+ conventional dendritic cells (cDC) and CD16- monocytes. BDCA-3+ cDC are analagous to mouse CD8+ cDC which are specialized in antigenic cross-presentation in complex with MHC class I molecules. In mouse, CLEC9a is additionally expressed on plasmacytoid dendritic cells. CLEC9a ligation enhances antigen uptake and processing, leading to presentation on MHC class I and cytotoxic T cell (CTL) priming. In mouse, CLEC9a recognizes normally intracellular determinant(s) of necrotic cells and mediates their uptake by the dendritic cell. The subsequent antigenic cross-presentation to CTL is important for clearing necrotic cellular debris. CLEC9a signaling triggers activation of the tyrosine kinase Syk. Applications: Suitable for use in Binding Inhibition, Western Blot and Immunohistochemistry. Other applications not tested. Recommended Dilutions: Western Blot: 1ug/ml with human CD14+ peripheral blood mononuclear cells (PBMC). Reducing conditions. Immunohistochemistry: 5-15ug/ml using human CD14+ peripheral blood mononuclear cells (PBMC). Binding Inhibition: The binding of recombinant human CLEC9a Fc Chimera (C5839-73K, 100ng/ml) to a ligand expressed in Fas Ligand-treated A20 mouse B cell lymphoma cell line was maximally inhibited (>80%) by 10ug/ml of this antibody as detected by Flow Cytometry. Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized and reconstituted products are stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
- Versandbedingungen:
- Blue Ice